Navigation Links
Lota S. Zoth joins NewLink's Board of Directors; heads Audit Committee
Date:11/7/2012

AMES, Iowa, Nov. 7, 2012 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that Lota S. Zoth has accepted appointment to its Board of Directors and will act as Chair of its Audit Committee.

Ms. Zoth was Chief Financial Officer at MedImmune, Inc at the time the company was sold to AstraZeneca in 2007.  Over her 30-year career, she held a number of senior financial positions at MedImmune, and other publicly-traded companies, including Marriott International, PepsiCo Inc., Sodexo (formerly Sodexho Marriott) and PSINet.  Ms. Zoth, a certified public accountant, began her career as an auditor at Ernst & Young, LLP.  Currently, she serves as a board member and audit committee chair on several public, private and non-profit boards.

"We are very pleased to bring Lota's insights to NewLink's Board as we continue to advance our promising drug candidates through clinical trials," commented Dr. Charles Link, Chairman and Chief Executive Officer of NewLink. "The first-hand experiences she has as an executive and board member in the biopharmaceutical industry will be very valuable to NewLink as we grow our company."

"In addition, as previously announced, two of NewLink's long serving Board members, David J. Lundquist and Sarah Alexander, did not stand for reelection at our recent shareholder's meeting," said Dr. Link.  "We appreciate Dave and Sarah's thoughtful advice and counsel as we grew from a small private research based company to a public company well into Phase 3 pivotal clinical trials."

About NewLink Genetics Corporation

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve treatment options for cancer patients. NewLink's portfolio includes biologic and small-molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink's product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens. NewLink's lead product candidate, algenpatucel-L (HyperAcute® Pancreas) is being studied in a Phase 3 clinical trial in surgically resected pancreatic cancer patients (under a Special Protocol Assessment with the U.S. FDA) as well as in a separate study in locally advanced pancreatic cancer patients. NewLink has recently launched an adaptive design Phase 2B/3 clinical trial of tergenpumatucel-L (HyperAcute Lung) in patients with non-small cell lung cancer. NewLink is developing indoximod (d-1-methyltryptophan, or D-1MT), a small-molecule, orally bioavailable product candidate from NewLink's proprietary indoleamine-(2, 3)-dioxygenase, or IDO, pathway inhibitor technology. NewLink is studying indoximod in various chemotherapy and immunotherapy combination studies independently and in collaboration with the National Cancer Institute. For more information please visit http://www.linkp.com. Patient information is available at http://www.pancreaticcancer-clinicaltrials.com.

Contact:
Gordon Link
Chief Financial Officer
515-598-2925
glink@linkp.com


'/>"/>
SOURCE NewLink Genetics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Thom Rowland Joins Arbor Pharmaceuticals as Vice President of Commercial Operations
2. Michael Epstein joins MedSpan Research as Director, Research Services
3. Kaiser Permanente Joins Rock Health to Support Digital Innovation in Health Care
4. Christopher Mennone Joins Surefire Medical Team As International Business Director
5. Sage Products Joins APIC Strategic Partner Program
6. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
7. Robert G. Savage, Former Worldwide Chairman, Johnson & Johnsons Pharmaceuticals Group, Joins Board of Nuovo Biologics, LLC
8. Jeffrey Wasserstein Joins Greenhill as Managing Director Focused on the Pharmaceutical Sector
9. Gerald E. Quirk Joins Choate, Hall & Stewart LLP as Co-Chair of Life Sciences Group
10. Dr. Magnus Persson Joins Cerecors Board of Directors
11. Joseph Rogers Joins SRI International as Executive Director of New Health Sciences Section in Biosciences Division
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2019)... ... September 13, 2019 , ... ... (WMIS) annual congress in Montreal provided a plethora of breakthrough research studies ... Artificial Intelligence (AI) to detect breast cancer, response prediction of cancer immunotherapies ...
(Date:9/14/2019)... TAMPA, Fla. (PRWEB) , ... September 13, 2019 ... ... Carastro Engineering and honored guests joined together to celebrate the structural topping out ... Sept. 10. , The expansion project will include a new six-story patient tower ...
(Date:9/12/2019)... ... September 12, 2019 , ... ... cycle management services, integrated practice management, and patient engagement solutions, announced today ... National User Conference (NUCON) 2019 . The annual conference features informative ...
Breaking Medicine Technology:
(Date:9/17/2019)... ... September 17, 2019 , ... Drs. Charles Felts and ... teeth in Chattanooga, TN for customized full mouth dental implants with TeethXpress® ... one day, providing a permanent tooth replacement solution for patients who struggle with ...
(Date:9/17/2019)... ... September 17, 2019 , ... Specialty Technical ... updated International Audit Protocol Consortium (IAPC) EHS audit protocol for Japan . ... scope of their EHS regulatory obligations and rapidly collect, share, archive, and export ...
(Date:9/14/2019)... , ... September 13, 2019 ... ... (WMIS) showcased several first-in-human studies on the detection and treatment of infectious ... examples of these ground-breaking studies were noninvasive detection of residual HIV infected ...
(Date:9/11/2019)... ... September 11, 2019 , ... A September 2 article ... weight loss surgery were significantly less likely to suffer heart attacks, strokes, kidney failure, ... bariatric surgery. Los Angeles-based weight loss surgery specialists Dr. Feiz and Associates says the ...
(Date:9/11/2019)... ... 11, 2019 , ... Autopsies don’t lie. They report the causes of ... Methamphetamine permanently harms the heart. It increases risks of heart attack and death. ... how the damage occurs. , An August 1, 2019 article in ...
Breaking Medicine News(10 mins):